AU710059B2

AU710059B2 - 4,5-dihydronaphth(1,2-C)isoxazoles and derivatives thereof having CNS activity

Info

Publication number: AU710059B2
Application number: AU14126/97A
Authority: AU
Inventors: Nicholas J. Hrib
Original assignee: Hoechst Marion Roussel Inc
Current assignee: Aventis Pharmaceuticals Inc
Priority date: 1996-01-05
Filing date: 1996-12-12
Publication date: 1999-09-09
Anticipated expiration: 2016-12-12
Also published as: NO983100D0; JP3161737B2; BR9612578A; EP0874833A1; KR19990077033A; AU1412697A; CA2241845A1; AR005347A1; HUP9903706A3; JPH11510816A; NO983100L; HUP9903706A2; KR100308748B1; NZ325587A; ZA9725B; CN1214046A; WO1997025317A1; CA2241845C; IL125197A0

Description

-1- 4,5-DIHYDRONAPHTH[1,2-c]ISOXAZOLES AND DERIVATIVES THEREOF HAVING CNS ACTIVITY The present invention is directed to certain novel compounds and their use as pharmaceutical agents having unique central nervous system activity.

This invention relates to 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof, and their use as serotonin 5-HT 3 antagonists, which may be useful for the treatment of anxiety, psychiatric disorders, schizophrenia, nausea, vomiting and the control of drug dependency, of general formula -0

A

x A

(CH

2 )n Where A is hydroxy, chloro, a group of the formula o 0 N (CH2)m 15 Ri a group of the formula o* a 20 a group of the formula 2.f.

C \WINWORDLENNYM\SPECNKI\14126-97 DOC Ri

N

or 0 a group of the formula 0 NO where R, is hydrogen, an alkyl group of 1 to 6 carbon atoms, optionally substituted with hydroxy, C 1

-C

6 alkoxy, amino; aryl or heteroaryl, optionally substituted with halogen, hydroxy or C1-C6 alkoxy; or benzyl optionally substituted with halogen, hydroxy or C,-C6 alkoxy; n is an integer of 1 or 2; Z is 10 N, CH or C(OH); m is an integer of 1 to 3; and X is hydrogen, hydroxy or C,-C6 alkoxy; the pharmaceutically acceptable salts thereof, the geometric or optional isomers thereof, or the racemic mixtures thereof, or hydrates thereof, where applicable.

o•* C \WINWORD\JENNYM\SPECNKI\14126-Q7 DOC The present invention also relates to a process for preparing these compounds, pharmaceutically acceptable addition salts thereof, as well as the pharmaceutical acceptable compositions thereof, and a method of using the compounds as seroton 5-HT, antagonists.

Throughout the description and claims of the specification the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.

Throughout the specification and appended claims, a given chemical formula or name shall encompass all stereo and optical isomers where such isomers exist. Additionally, a given chemical formula or name shall encompass the pharmaceutically acceptable additional salts thereof.

In a preferred embodiment of the invention are compounds of formula (I) wherein AN (C H,)m wherein C WINWOROUENNYWSPECNA11141M41 DCC R, is hydrogen, an alkyl group of 1 to 6 carbons, optionally substituted with hydroxy, C,-C6 alkoxy or amino substitution; aryl or heteroaryl, optionally substituted with halogen, hydroxy or C,-C6 alkoxy; or benzyl optionally substituted with halogen, hydroxy or C,-C6 alkoxy; n is an integer of 1 or 2; Z is nitrogen; m is an integer of 1 to 3; and X is hydrogen, hydroxy or alkoxy.

More preferred, are compounds of formula wherein R, is hydrogen, or an alkyl group of 1 to 3 carbons; n is 1; Z is nitrogen; m is 1 or 2; and C:\WINWORDUENNYM\SPECNKI\1 412697.DOC X is hydrogen.

The novel compounds of the present invention and the intermediates thereto may be prepared by the reaction sequence illustrated hereinbelow. The substituents Z, m, n and X are generally as defined above unless otherwise indicated.

N, OH

N-O

O/OH

X- X OH POC13 2 (CH2)n (CH2)n Et 3

N

-0

-O

X C H-A 4 (CH2)n base .(CH2)n 1* 1 According to the preparation scheme, hydroxyisoxazoles 3 are prepared from oximes 2 in a solvent such as tetrahydrofuran (THF) at a temperature of from about 25°C to about reflux temperature of the solvent for a period of from about 15 0.25 to about 4 hours according to the methods of Griffiths and Olofson. In general, a solution of the oxime 2 in a solvent such as tetrahydrofuran is treated with n-butyllithium and the solution of the resulting dilithio salt is poured onto carbon dioxide. The mixture is then acidified to provide 3-hydroxyisoxazole 3.

(Jerome Griffiths, et al., J. Chem. Soc. C. 974 (1971) and G.N. Barber and R.A.

20 Olofson, J. Org. Chem. 43, 3015 (1978).

The hydroxyisoxazoles 3 are converted to chloroisoxazoles 4 via C \VVINVVORD)ENNYM\SPECNKI 1412 6 97 DOC 0 WO 97/25317 PCT/US96/1 9569 treatment with phosphorous oxychioride in the presence of a suitable base, such as triethylamine, at a temperature off from about 1006 to about 200%C for a period of from about 0.25 to about 4 hours in a manner similar to that utilized by Adembri ec al. Adembri and P.Tedeschi, Bull. Sci. Fac. Chi=. Ind.

Bologna 23, 203 (1965)). Intermediates 4 are treated with an appropriate nucleophile H-A (wherein A is defined hereinbefore) at a temperature of from about 100* to about 200* C with or without added base in an appropriate solvent, such as Nmethylpyrrolidinone, to provide the novel compounds 1 of the invention.

These compounds may be prepared by the following representative examples. The examples are exemplary and should not be construed as limiting the invention disclosed herein.

EXAMPLE 1 3-Chloro-4,5-dihydronaphthtl,2-clisoxazole

N-

0 N-0

-I/

To a stirred mixture of 4,5-dihydronaphth[l,2-clisoxazol-3- (3aH)-one (7.25g, 38.77mmol) in phosphorus oxychioride (10.84m1, 116.3inmol), triethylamine (5.40m1, 38.77mmol) was added WO 97/25317 PCTIUS96/19569 dropwise. After completion of addition, the Mixture was heated to reflux while stirring. After 2 hours, no starting material remained as shown by TLC (silica, ethylacetate (EtOAc)]I. The mixture was cooled to room temperature, poured into 300 ml of ice water, and extracted with CH 2

CI

2 The organic extracts were combined, dried over MgSO, and concentrated in vacuc. The resultant solid was filtered through silica using CH 2 Cl 2 eluent to provide 6.2g of crude product. This crude product was recrystallized from a minimum of heptane to provide a product as needles, mp of 57-59*C, homogeneous by thin layer chromatography (TLC) silica, CH 2 Ci 2 Rf-O- 0.81. The Infrared (IR) (CHCI 3 nuclear magnetic resonance (NMR) (CDCl 3 and Mass Spectrum (Wi'205, El, 70eV) were consistent with the structure. The yield was 5.417g (26.4mmol, 68.16%).

Elemental Analysis Calculated Found C 64.25 64.02 H 3.92 3.86 C1 17.24 N6.81 6 .77 0 7.18 EXAMPLE 2 3-(4-Methyl-l-.piperazinyl)-4, 5-dihydronaphth[l,2-c] isoxazole WO 97/25317 PCT/US96/1 9569 N-0 17 ZN A stirred mixture of 3-chloro-4,5-dihydronaphthtl 2clisoxazole (2.65g, 12.93mmol), N-methyl piperazine (30m1, 270.4mmoi) and K 2 CO, (3.5 7 g, 25.87mmo1) under N 2 was lowered into an oil bath preheated to 150*C. The mixture was heated while stirring under N 2 for 2 hours. At that time, TLIC [CH 2 C1 showed no remaining starting material. The mixture was removed from the heating bath and allowed to cool to room temperature. it was then partitioned between heptane/Ho. The heptane phase was washed with water, dried over MgSO 4 1 filtered and concentrated in vacuc to yield a solid. This crude product was recrystallized from heptane/ether (Et.O) to provide the product as needles, mp of 92-94*C, homogeneous by TLC [silica, 1:1

CH

3 OH:EtQLAc, Rf-0.39). The IR (CHCl 3 NHP. (CDCl 3 and Mass Spectrum (M*-269, EI, 70eV) were consistent with the structure.

The yield was 1.2555g (4.67rnmol, 36.09%).

WO 97/25317 PCTIUS96/1 9569 Elemental Analysis Calculated Found C 71.35 71.34 H 7.11 6.98 N 15.60 15.78 o0 1 5.94 EXAMPLE 3 2 -Hydroxyethyl)-l-piperazinyl)-4,5-dihydronaphth[, 2 clisoxazoie

N-

0 N-0 I Nh A stirred mixture of 3-chloro-4, 5-dihydronaphth(1,2clisoxazole (3.0g, 14.63mmol), l-( 2 -hydroxyethyl)--piperazine (1 7 .95m1, f46.3mmol) and K(203 (4.1g, 29.Jznmol) in 18m.1 of Nmethly-pyrrolidinone under N 2 was lowered into an oil bath preheated to 150*C. The mixture was heated while stirring under

N

2 for I. hour. At that time, TLC (CH 2

CI

2 showed no remaining starting material. The mixture was removed from the heating bath, allowed to cool to room temperature, and diluted with H 2 0.

Upon the addition of heptane, a solid precipitated. The solid was collected, washed with heptane and H.0, and dried in vacuc WO 97/25317 PCT/US96/1 9569 (Q.1mim) at 85-C overnight to provide pure Product, mP ofA 13-7- 13l8-,C, homogeneous by TLC [silica, 1: 1 CH 3 OH:EtOAc, Rf~o. 671 The IR (CHCl 3 N4M (CDCl 3 and Mass Spectrum (M*-299, EI, 7 OeV) were consistent with the structure. The yield was 2 6 03g (8.7Ommol, 59.47%).

Elemental Analysis ____Calculated Found C 68.21 68.12 H 7.07 7.01 N14.04 14.14 0 10.69 EXAMPLE 4 3- (l-Homopiperazinyl)-4,5-dihydronaphth(1,2-cl isoxazole A stirred mixture of 3 -chloro-4,5-dihydronaphth[1,2clisoxazole (3.0g, 14.63 mmol) homopiperazine (14.66g, 146.3 mmol) and K2C0, (4.04g, 29.3mmol) in 16m1 of N-methylpyrrolidinone under N 2 was lowered into an oil bath preheated to 150*C. The mixture was heated while stirring under N 2 for 45 minutes. At that time, TLC (CH 2 Cl 2 showed no remaining WO 97/25317 PCTIUS96/1 9569 starting material. The mixture was removed from the heating bath, allowed to cool to room temperature, diluted with H,0 and extracted with Et 2 Q. The Et 2 O phase was dried over MgSO 4 filtered and concentrated in vacuc. The crude solid obtained was recrystallized from heptane/EtO and dried in vacua (0.1mm) at 85*C overnight to provide pure product, mp of 79-81%c, homogeneous by TLC (silica, 1:1 CH30H:Et0Ac, Rf-0.17] T he I.R (CHCI,) M (CD)C13) and Mass Spectrum El, 70ev) were consistent with the structure. The yield was 1.969g 7 .32mmol, 50.03%).

Elemental Analysis ____Calculated Found C 71.35 71.45 H 7.11 7.29 N15.60 15.56 0 5.94 EXAMPLE 3- (1-Piperazinyl) 5-dihydronaphth(1, 2-c] isoxazole N-0 N -0 I/ I

N

WO 97/25317 PCT/US96/19569 A stirred mixture of 3 -chloro- 4 ,5-dihydronaphth 1 2 Sclisoxazole (5.0g, 24.4mmol), piperazine 34 .2g, 39.mml and

K

2 C0 3 (6.739, 48.7mmol) in 40m. of N-methylpyrroliinone under N2 was lowered into an oil bath preheated to 150*C. The mixture was heated while stirring under N, for 45 minutes. At that time, TLC (CH- 2 C1 2 showed no remaining starting material. The mixture was removed from the heating bath, allowed to cool to room temperature and extracted with Et 2 O. This organic phase was washed twice with H 2 0, dried over MgSO 4 filtered and concentrated in vacuc to obtain a crude solid. The solid was collected, recrystallized from heptane/Et 2 O and dried in vacuo (0.1mm) at W5C to provide pure product, mp of 97-99-C, homogeneous by TLC (silica, 1:1 CH 3 0H:CH 2

CI

2 Rt-0.351. The IR (CHC1 3 NMiR (CDC1 3 and Mass Spectrum (W-255, EI, 70eV) were consistent with the structure. The yield was 3.372g (l3.22mmol, 54.19%).

Elemental Analysis Calculated Found C 70.56 70.38 H 6.71 6.67 N 16.46 16.47 0 6.27 WO 97/25317 PCT/US96/I 9569 EXAMPLE 6 3-( 4 -Benzyl-l-piperazinyl) 4 ,5-dihydronaphth[1,2-c~lisoxazole N -0 N -0 I N A stirred mixture of 3 -chloro-4,5-dihydronaphth(1,2clisoxazole (2.0g, 9.7Smmol), l-benzylpiperazine (l7ml, 9 7 .5mmol) and K 2 C0 3 (2.7g, l9.5mm 1) in 18ml of Nrethylpyrrolidinone under N 2 was lowered into an oil bath preheated to 150*C. The mixture was heated while stirring under

N

2 for 2 hours. At that time, TLC (CH 2 Cl 2 showed no remaining starting material. The mixture was removed from the heating bath, allowed to cool to room temperature and extracted with heptane. The organic phase was dried over MgSO 4 filtered and concentrated in vacua to obtain a crude solid. The solid was collected, titrated with Et 2 O, recrystallized from Et 2 O and dried in vacuo (0.1mm) at 85'C to provide pure product, mp of 164- 166'C, homogeneous by TLC [silica, 1:1 EtOAc, Rf-0.80]. The IR

(CHCI

3 NMR (CDCI,) and Mass Spectrum (M*-345, El, 70eV) were consistent with the structure. The yield was 1.219g (3.S3mmol, 36.24%).

WO 97/25317 PCT/US96/1 9569 Elemental Analysis Calculated Found C 76.49 76.49 H 6.71 6.85 N 12.16 12.09 0 4.63 EXAMPLE 7 3-Hydroxy--8-methoxy-4, 5-dihydronaphthf 1,2-c] isoxazole

.QH

To a mechanically stirred mixture of l-methoxy a-tetralone oxime (5.0g, 26.l8romol) in anhydrous THF (iS0ml) at OOC under N 2 was slowly added n-butyl-lithium (n-BuLi) (23.Oml of a solution in hexane, 57.60mmol). The mixture was stirred at 0*C for 30 minutes, then C0 2 gas was bubbled into the solution. (As this addition progressed, a solid precipitate began to form).

After 15 minutes, CO 2 addition was stopped and N. flow was restored. The thick mixture was stirred and warmed slowly to room temperature for l14 hours, then 6N H 2 S0 4 (150MI) was slowly added which dissolved the solids. The TLC showed traces of starting oxime and a mixture of desired product and an WO 97/25317 PCT/US96/1 9569 intermediate which was not isolated. Stirring was Continued for 4 hours at which time the intermediate was completely converted to product. The mixture was extracted exhaustively with EtOAc.

The organic fractions were combined, washed once with H 2 0, once with brine, dried over MgSO 4 and filtered. Concentration in vacuo caused the precipitation of a solid which was collected, titrated with EtOAc, and dried in vacuo to provide the product as a solid, mp of 135-138*C, homogeneous by TLC (silica, 10:90

CH

3 OH:EtOAc, RfO0.46]. The (KBr), NMP. (DMSO-d 4 and Mass Spectrum (W-217, EI, 70eV) were consistent with the structure.

The yield was 2.0496g (9,45mmol, 36.08%).

Elemental Analysis Calculated Found C 66.35 66.02 H 5.10 5.03 N 6.45 6.22 0 22.10 EXAMPLE 8 3 -Chloro-8-methoxy-4,5-dihydronaphth(1,2-c] isoxa Lzole

CIT

3 WO 97/253 17 PCT/US96/1 9569 To a stirred mixture of -J-hydroxy-8-methoxy-4,5dihydronaphth[l,2-clisoxazole (10.0g, 4 6 .Q8mmol) in phosphorus oxychioride (12.8m1, 137.3mmol), triethylamine (6.42m1, 46.O8mmol) was added dropwise. After completion of addition, the mixture was heated to reflux: while stirring. After 4 hours, no starting material remained as shown by TLC (silica, EtOAc].

The mixture was cooled to room temperature, poured into 400m1 of ice water, and extracted with heptane. The organic extracts were combined, dried over MgSO 4 filtered and concentrated in vacuo. Concentration of the filtrate in vacuc caused a solid to precipitate. The solid was triturated with heptane and driedi in vacuo to provide the product as needles, mp of 55-57*C, homogeneous by TLC (silica, CH 2 Cl 2 RfinO.451. The IR (CHCl,), NMP, (CDCl 3 and Mass Spectrum (M-235, El, 70eV) were consistent with the structure. The yield was 7 .75g (32.98mmol, 71.57%).

Elemental Analysis Calculated Found C 61.16 61.29 H 4.28 4. 16 Cl 15.04 N 5.94 5.90 0 13.58 WO 97/25317 PCT/US96/19569 EX.AMPLE 9 3-((l-Methyl-4-piperidiflyl)oxy]-4,5-dihydronaphth[1,2ci isoxazole

CH

3 N-0 N-0 1/ /1 To a stirred solution mixture of 4-hydroxy-N-methyl piperidine (5.05g, 43.89mmol) in 1O0mI of N-methylpyrrolidinone under N, was added NaH (1.75g of a 60% dispersion in oil, 43.89mmol). The mixture was stirred at room temperature for minutes, then a solution of 3-chloro-4,5-dihydronaphth[1,2clisoxazole (3.0g, 14.63rnmol) in 15m. N-methylpyrrolidinone was added in one portion. The stirred mixture was lowered into an oil bath preheated to 150*C. After 20 minutes TLC (CH 2 Cl 2 I1 showed no starting materials remaining. The mixture was removed from the heating bath and allowed to cool to room temperature.

It was then partitioned between heptane/H 2 0. The heptane phase was washed with water, dried over MgSO 4 filtered and concentrated in vacuo. This crude oil obtained was taken up in Et 2 O, filtered, and the HCl salt precipitated by the addition of ethanolic HCl. This salt was recrystallized from CH 2 Cl 2 /Et 2 o to WO 97/25317 PCTIUS96/19569 provide the product as a solid, mp off 14 7 -150"Cl homogeneous by TLC [silica, 1: 1 CH3OH:EtOAc, Rf-0. 02J. The IR (KBr), NM.R (CDCl,) and Mass Spectrum (M'+1-285, CI, methane) were consistent with the structure. The yield was 1.

29 94g 4 .O5mmol, 36.09%).

Elemental Analysis ___Calculated Found C 63.65 63.55 H 6.60 6.63 Cl 11.05 N8.73 8.78 0 9.97 EXAMPLE

CH

3 N -0

CH

3 N -0 A stirred mixture of 3-chloro-8-methoxy-4,5dihydronaphth[1,2-cljsoxazole (2.0g, 9.5lmmol), piperazine 7 .0g, 80.6mmol) and K 2 C0 3 (2.4g, l 7 .lmmol) in 8.OmlI of Nmethylpyrrolidinone under N 2 was lowered into an oil bath preheated to 1500C. The mixture was heated while stirring under

N

2 for 20 minutes. At that time TLC [CH 2 Cl 2 showed no starting WO 97/253 17 PCTIUS96/19569 material remained. The mixture was removed from the heating bath and allowed to cool to room temperature. Upon dilution of the reaction mixture with H2O, a solid precipitated which was collected and dried in vacua to provide pure product, mp of 86- 8 8 C, homogeneous by TLC (silica, 1: 1 CH 3 0H: CH 2 Cl 2 Rf-0. 37 The IR (CHCI,) NMR (CDCI 3 and Mass Spectr-um (M*-285, EI, 7 OeVi were consistent with the structure. The yield was 1.932g (6.78mmol, 79.66%).

Elemental Analysis Calculated Found C 67.35 66.99 H 6.71 6.77 N .14.73 14.53 0 11.211 EXAMPLE 11 3- (l-Homopiperazinyl)-B-methoxy-4, 5-dihydronaphth(1,2ci isoxazole

CH

3 N- 0

CH

3 N -0

-O

A stirred mixture of 3-chloro-8-methoxy-4,5dihydronaphth[1,2-clisoxazole (2.66g, 11.32inmol), homopiperazine WO 97/25317 PCTIUS96/1 9569 (11.40g, ll3.2mol) and K,CO, (3.13g, 2 2.68mmol) lO.Ornj o N -methylpyrroidinone under J 2 was lowered into an oil bath preheated to 150*C. The mixture was heated while stirring under N, for 20 minutes. At that time, TLC (CH2Cl 2 showed no starting material remained. The mixture was removed from the heating bath, allowed to cool to room temperature and diluted with H 2 0, which caused a solid to precipitate. The crude solid was dried, recrystallized from Et 2 Q and dried in vacuo, (0.1mm) at 950C, to provide pure product, mp of 106-109*C, homogeneous by TLC: (silica, 1:1 CH 3

OH:CH

2 Cl 2 Rt-0.181. The IR (CHC1)), NI4R (CDCI 3 and Mass Spectrum (M-299, El, 70eV) were consistent with the structure. The yield was 1.7948g (6.00mmol, 53.03%).

Elemental Analysis Calculated Found C 68.21 68.24 H 7.07 7.11 N 14.04 14.00 0 10.69 WO 97/25317 PCT/US96/1 9569 EXAMPLE 12 3 (p-Chlorophenyi) 4 -hydroxy-piperidinyl) -e-methoxy-4, dihydronaphth isoxazole

CH

3 N CH 3 N-0 7 N OH A stirred mixture of 3 -chioro-8-methoxy-4,sdihydronaphth(1,2-c)isoxazole (2.0g, 8 .5lmmol), 4-p chlorophenyi)-4-hydroxy-dipiperidine 3 6g, 1 7 .02mol) and K 2 C0 3 (2.35g, 1 7 .02mmol) in Emi of N-methylpyrrolidinone under ?Nwas lowered into an oil bath preheated to 150*C. The mixture was heated while stirring under N 2 for 1 hour. At that time, TLC

(CH

2 C1 showed no remaining starting material. The mixture was removed from the heating bath and allowed to cool to room temperature. Upon dilution of the reaction mixture with H 2 0, a solid precipitated which was recrystallized from EtOAc and dried in vacuc (0.1mm) at 85*C to provide pure product, mp of 174- 177*C, homogeneous by TLC [silica, 2:1 heptane:EtOAc, Rf-0.2631.

The IR (CHCl,), HM (CDCI,) and Mass Spectrum (M'-410, were consistent with the structure. The yield was 2.3798g (5.E60mmol, 68.20%) WO 97/25317 PCTIUS96/19569 Elemental Analysis Calculated Found C 67.23 67.24 H5.64 N 6.82 87 0 11.68 EXAMPLE 13 3 -i(endo)8-Methy8-aa icyc3.-lo[t3l)OxtYl]- 8 to 4, 5-dihydronaphth[1, 2-cl isoxazole

CH

3 N -0

CH-

3 N-0 c 4 To a stirred mixture of tropine (5.41g, 3 8.Jlmmol) in 10 ml of (THF) under N 2 at 0"C was slowly added n-BuLl (1S.Oml of a solution in hexanes, 38.3lmmol). The mixture was stirred for 15 minutes while allowed to warm to room temperature, then a solution of 3-chloro-8-methoxy-4, S-dlhydronaphth[1,2-clisoxazole l2.

7 Emmcl) in 30m. N-methylpyrrolidinone was added in one portion. The internal temperature increased to 99-100*C and was maintained there. After 3 hours, TLC ICH.Cl 2 1 showed no starting material remaining. The mixture was removed from the heating bath and allowed to cool to room temperature, It was then WO 97/25317 PCTIUS96/1 9569 partitioned between heptane/H 2 0. The heptane phase was washed with H 2 0, dried over MgSC 4 filtered and concentrated in vacuo, whereupon it solidified. This crude solid was recrystallized from a minimum of heptane and dried in vacuo to provide the product as a solid, mp of 102-104*C, homogeneous by TLC [silica, 1:1 CH 3

OH:CH

2

CI

2 Rf=0.20]. The IR (CHCl,), NHR (CDC1 3 and Mass Spectrum CI, methane) were consistent with the structure. The yield was 1.

37 29g 4 .Oj8mmol, 31.64%).

Elemental Analysis ____Calculated Found C 70.57 70.47 H 7.11 7.25 N 8.23 8.14 0 14.10 EXAMPLE 14, 3 -[(endo--M~thyl--azaicyclo.2.oct3.yl)oxy]- 4 ,s dihydronaphth[1,2-c)isoxazole hydrochloride hemihydrate To a stirred mixture of tropine (4.4g, 31.l6mmol) in WO 97/25317 PCT/US96/19569 of THF under N, at O'C was slowly added n-BuLi (1 2 .47ml of a solution in hexanes, 31.16mmol). The mixture was stirred for minutes while allowed to warm to room temperature, then a solution of 3 -chloro- 4 ,5-dihydronaphth[1,2-c]isoxazole (2.13g, 10.39mmol) in 30ml N-methylpyrrolidinone was added in one portion. The stirred mixture was lowered into an oil bath preheated to 150'C. The internal temperature increased to and was maintained there. After 3 hours, TLC (CHC1 2 showed no remaining starting material. The mixture was removed from the heating bath and allowed to cool to room temperature. It was.

then partitioned between heptane/H0. The heptane phase was washed with H 2 0, dried over MgSO,, filtered and concentrated in vacuo, to provide the free base as an oil, which resisted attempts at crystallization. The oil was taken up in Et,O and the HC1 salt was precipitated by the addition of ethanolic HC1.

This crude solid was recrystallized from Et 2

O/CHC

2 1 and dried in vacuo at 85C to provide the product as a solid, mp of 167- 170'C, (darkens at ca. 150'C) homogeneous by TLC [silica, 1:1 CHOH:CHCl 2 Rf=0.14]. The IR (CHCl 3 NMR (CDC1,) and Mass Spectrum (M*+1l311, CI, methane) were consistent with the structure. Analysis and NMR confirmed the hemihydrate structure. The yield was 1.268g (3.563mmol, 34.29%).

WO 97/25317 PCT/US96/1 9569 Elemental Analysis Calculated Found C64.12 64.25 H 6.80 6.77 Ci N j 7.87 f 7.70 09.23[iII i J EXAMPLE 3-Cl- (6-Fluorobenzisoxazol-3-yl) -piperidinyl) 8 -methoxy-4, dihydronaphtht1, 2-cl isoxazole

CH

3 N-0 CH 3

N-

A stirred mixture of 3-chloro-8-methoxy-4,5dihydronaphthtl,2-clisoxazole (2.0g, 8.Slmmol), 4-(6f luorobenzi soxazol-3 -yl) -piper idine (2.8g, 1 2 7 6mmol) and K 2 C0 3 (2.35g, 17.O2mmol) in l0mi of N-methylpyrrolidinone under N 2 was lowered into an oil bath preheated to iS0*C. The mixture was heated while stirring under N 2 for 90 minutes. At that time TLC

(CH

2 Cl 2 showed no remaining starting material. The mixture was removed from the heating bath and allowed to cool to room WO 97/25317 WO 9725317PCTIUS96/1 9569 temperature. Upon dilution of the reaction mixture with H'O' a -solid precipitated which was collected, dried, dissolved in

CH

2 Cl 2 and filtered through neutral alumina. The fractions containing desired product were combined and concentrated, and the resultant solid obtained was triturated with Et 2 O to provide a solid, mp of 191-183*C, homogeneous by TLC [silica, 2:1 lHeptane:EtCaAc, Rt=O.15]. The IR (CHCl 3 NMR (CDCI3) and Mass Spectrum (W-419, El, 70eV) were consistent with the structure.

The yield was 1.1318g (2.7Ommol, 31.70%).

Elemental Analysis ___Calculated Found C 68.72 68.47 H 5.29 5.28 F 4.53 N 10.02 9.97 0 11.44 WO 97/25317 LIPCTIUS96/1 9569 EXAMPLE 16 3 4 2 -Oxo-1-benzimidazolinylJpiperilinyl) 8 -methoxy-4,sdihydronaphth(l, 2-cl isoxazoje CH3

CH

3 N -O Aa 0 N NH A stirred mixture of 3 -chlaro-8-methoxy-4,5dihydronaphthtl,2-clisoxazole (2.57g, 1O.9mmal), 4 -(2-oxo-lbenzimidazolinyl)piperidine (4.

7 4g, 21.6mmol) and K 2 C0 3 (3.02g, 2l.8mmol) in 12m1 of ?-methylpyrrolidtnone under N~ was lowered into an oil bath preheated to 1500C. The mixture was heated is while stirring under N 2 for 4 hours. At that time, TLC (CH 2 C1 2 showed no remaining starting material. The mixture was removed from the heating bath and allowed to cool to room temperature.

Upon dilution of the reaction mixture with H 2 0, a solid precipitated which was collected, dried, dissolved in d11 2 C1 2 and filtered through neutral alumina using CH 2 C1 2 and then 1 :1

CH

2 Cl 2 :Et 2 O. The fractions containing desired product were combined and concentrated, and the resultant solid obtained was triturated with EtOAc and dried in vacuo (0.1mm H{g, 850C) to provide a solid, mp of 211-214*C, homogeneous by TLC (silica, WO 97/25317 PCTI US96/1 9569 EtOAc, Rf-0.38). The IR (CH-Cl3}, NMR and mass Spectrum (W=-416, El, 70eV) were consistent with the structure. The yield was 1.602g (3.85mmol, 33.33%).

Elemental Analysis Calculated Found C 69.21 68.88 H 5.81 5.90 N 13.45 13.10 0 11.52 EXAMPLE 17 (Quinuclidin-3-yl)oxy]-8-methoxy-.4,5..dihydronaphthtI, 2 ci isoxazole hydrochloride

CIT

3 N-0

CIT

3 N -O To a stirred mixture of 3-quinuclidino. (4.87g, 38.28mmol) in l0mi of THF under N 2 at 0*C was slowly added n-BuLi (15.32g of a 2.5M solution in hexanes, 38.28mmol). The mixture was stirred for 10 minutes while allowing to warm to room temperature, then a solution of 3 -chloro- 8 -methoxy-4,5-dihydronaphth[1,2- WO 97/25317 PCT/US96/19569 c]isoxazole (3.0g, 12.

7 6mmol) in 30ml N-methylpyrrolidinone was added in one portion. The stirred mixture was lowered into an oil bath preheated to 150'C. The internal temperature increased to 85°C and was maintained there. After 3 hours, TLC [CH 2 ,C1, showed no remaining starting material. The mixture was removed from the heating bath and allowed Eo cool to room temperature.

It was then partitioned between heptane/H 2 0. The heptane phase was dried over MgSO 4 filtered and concentrated in vacuo to provide the free base as an oil. The oil was taken up in Et,O and the HCI salt was precipitated by the addition of ethanolic HC1. This solid was collected and dried in vacuo (O.1mm Hg, to provide the product as a solid, mp of 133-136'C, homogeneous by TLC (silica, 1:1 CH 3 OH:CHC1 Rf=0.23]. The IR (KBr), NMR (DMSO-d,) and Mass Spectrum (M*+1-326, El, 70eV) were consistent with the structure. The yield was 0.965g (2.39mmol, 18.79%).

Elemental Analysis Calculated Found C 62.89 62.91 H 6.39 6.28 Cl 9.77 N 7.72 7.51 0 13.23 i WO 97/25317 PCT/US96/19569 EXAMPLE 18 5,6-Dihydro-4H-benzo(6,7]cyclohept[l,2-clisoxazol-3-ol

OH

N

NO

To a mechanically-stirred mixture of l-benzosuberone oxime (10.0g, 5 7 .lmmol) in anhydrous THF (200ml) at OC under N, was slowly added n-BuLi (50.3ml of a 2.5M solution in hexane, 1 25 .62mmol). The mixture was stirred at 0*C for 30 minutes, then CO 2 gas was bubbled into the solution. After 15 minutes, CO, addition was stopped and N 2 flow was restored. The thick mixture was stirred and warmed slowly to room temperature for 1 hours, then 6N HSO, (220ml) was slowly added, which dissolved the solids. Stirring was continued for 18 hours, at which time the TLC [EtOAc] showed a mixture of starting oxime and product (starting oxime was best visualized using 2:1 heptane:EtOAc eluent). The mixture was poured into a separatory funnel, and the organic phase drawn off. The aqueous phase was extracted with EtOAc, and the organic phase and the EtOAc extracts were combined, washed with H 2 0, dried over MgSO, and filtered.

Concentration in vacuo caused the precipitation of a solid which was collected and dried in vacuo to provide the product as a WO 97/25317 WO 97/53 17PCT[US96/19569 solid, mp of 165-168*C, homogeneous by TLC (silica, Et,, -Rt=0.28] The IR (KBr), NMR (DMSO-d,,) and Mass Spectrum (M'=201, EI, 70 eV) were consistent with the structure. The yield was 3.0324g (15.O9mmol, 26.42%).

Elemental Analysis Calculated Found C71.63 71.45 H 5.51 5.50 6.96 6.91 0 15.90 EXAMPLE 19 3- (2-Oxo-1-benzimidazolinyl) piperidinyl) dihydronaphth(1,2-clisoxazole hemihydrate N-0 N -0 Na N N H H I 2 0 A stirred mixture of 3 -chloro-4,5-dihydronaphthfl,2clisoxazole (3.1g, 15.l2mmol), 4 2 -oxo-l-benzimidazolinyl)piperidine (8.2g, 37.8mmol) and K 2 C0 3 (4.2g, 30.24mmol) in 18m1 of N-methylpyrrolidinone under N 2 was lowered into an oil bath WO 97/25317 PCT/US96/19569 preheated to 150'C. The mixture was heated while stirring under

-N

2 for 90 minutes. At that time, TLC (CHC,) showed no remaining starting material. The mixture was removed from the heating bath and allowed to cool to room temperature. Upon dilution of the reaction mixture with H 2 0, a solid precipitated which was collected, dried, dissolved in CH 2 Cl, and filtered through neutral alumina using CHC1, and then 1:1 CH 2 Cl2:Et2.

The fractions containing desired product were combined and concentrated, and the solid obtained was recrystallized from EtOAc and dried in vacuo (0.1mm Hg, 110'C) to provide a solid, mp of 229-233'C, homogeneous by TLC [silica, EtOAc, Rf-0.54].

The IR (KBr), NMR (CDC1 3 and Mass Spectrum (M-386, EI, were consistent with the structure. Analysis and NMR confirmed a hemihydrate structure. The yield was 1.103g (2.79mmol, 18.45%).

Elemental Analysis Calculated Found C 69.82 70.25 H 5.86 5.64 N 14.17 14.22 0 8.28 WO 97/25317 PCT/US96/19569 Preferred pharmaceutically acceptable addition salts -include salts of inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids; as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric, and oxalic acids.

The active compounds of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, waters, chewing gums and the like.

These preparations should contain or form at least 0.5% of active compound, but may be varied depending upon the particular form and may conveniently be from about 4 to about 75% of the weight of the unit. The amount of compound present in such composition is such that a suitable dosage of active compound will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains from about 1.0 to about 300mgs of active compound.

The tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as WO 97/25317 PCT/US96/19569 microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel", corn starch and the like; a lubricant such as magnesium stearate or Sterotex®; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring may be added. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil.

Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings an flavors.

Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

For the purpose of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of the aforesaid compound, but may be varied from about 0.5 to about 30% of the weight thereof. The amount of compound in such composition is such that a suitable dosage of active compound will be obtained. Preferred compositions and WO 97/25317 PCT/US96/19569 preparations according to the invention are prepared so that a parenteral dosage unit contains from about 0.5 to about 100mgs of active compound.

The solutions or suspensions may also include the following components; a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

The compounds of the invention may be useful as antagonists on the coronary chemoreflex for the treatment of anxiety, psychiatric disorders, nausea and vomiting by virtue of their ability to bind to rat entorhinal cortex membranes.

3 H-GR 65630 Binding to Rat Entorhinal Cortex Membranes Studies have been performed to determine the affinity of the compounds of the invention for the 5HT, binding site in the brain. This study or assay may be useful for predicting the WO 97/25317 PCT/US96/19569 potential of compounds to exhibit antiemetic, anxiolytic or -atypical antipsychotic profiles.

Originally, it was believed that 5HT, binding sites existed only in the periphery. However, with the recent introduction of potent and selective 5HT 3 antagonist drugs such as GR65630, Zacopride, ICS 205 930 and MDL 72222 (Bemesetron, CsH,,CiNO 2 data from binding studies have indicated that 5HT, binding sites are also located in selected areas of the brain. The highest levels of 5HT, binding sites have been detected in limbic and dopamine containing brain areas (entorhinal cortex, amygdala, nucleus accumbens and tuberculum olfactorium) (Kilpatrick,

G.J.

et al. Identification and distribution of 5HT 3 receptors in rat brain using radioligand binding. Nature 330: 746-748). Besides possessing selective binding in dopamine rich areas, antagonists have been reported to block behavioral effects associated with certain drugs of abuse (nicotine and morphine) and to be active in behavioral tests predictive of anxiolytic activity. Based on these selective regional binding results and behavioral studies, 5HT 3 antagonists may have a therapeutic benefit in disease states believed to be associated with excessive dopaminergic activity, schizophrenia, anxiety and drug abuse.

WO 97/25317 PCT/US96/1 9569 In accordance with the above-discussed assay, a 0.05M of -Krebs-Hepes buffer, pH 7.4 was prepared as follows: 11.92g Hepes 10.52g NaCI 0.373g KCl 0.277g Cad 2 0.244g MgClz. 6H 2 0 q.s. to 1 liter with distilled bring pH up to 7.4 (at 46C) with SN NaOH [IHI-GR6563o (8 7 .OXi/mmol) was obtained from New England Nuclear. For .IC5() determinations: 3 H]-GP.6563o was made up to a concentration of 1.OnM in Krebs-Hepes buffer such that when iQ0,ul is added to each tube, a final concentration of O.4n( is attained in the 25Oki1 assay.

GR38032F was obtained from Research Biochemical Inc.

GR38032F was made up to a concentration of 500ti4 in Krebs-Hepes buffer. 5Oul of Krebs-Hepes were added to each of 3 tubes for determination of nonspecific binding (yields a final concentration of 1O0ksM in the 2SO0]. assay).

For most assays, a 50m~l stock solution was prepared in a suitable solvent and serially diluted with Krebs-Hepes buffer WO 97/25317 PCT/US96/19569 such that when 5041 of drug is combined with the total 2 assay, a final concentration from 10-' to 10-"M was attained.

Characteristically, seven concentrations may be used for each assay; however, higher or lower concentrations may be used, depending on the potency of the drug.

During tissue preparation, Male Wistar rats (15- 2 00g) were decapitated, the entorhinal cortex removed, weighed and homogenized in 10 volumes of ice cold 0.05M Krebs-Hepes buffer, pH 7.4. The homogenate is centrifuged at 4 8 ,000g for 15 minutes at 4'C. The resulting pellet was rehomogenized in fresh Kreba- Hepes buffer and recentrifuged at 48 ,000g for 15 minutes at 4'C.

The final pellet was resuspended in the original volume of icecold Krebs-Hepes buffer. This yielded a final tissue concentration of 1.2 to 1.6mg/ml with the addition of 100m1 to the assay. Specific binding was approximately 55 to 65% of the total bound ligand.

In conducting the assay, the following volumes were utilized: 1001 of Tissue suspension; 100,l of [(HI-GR65630; and 50g1 500M GR38032F (Vehicle for binding) or appropriate drug concentration WO 97/25317 PCT/US96/19569 Sample tubes were kept on ice for additions, then vortexed and -incubated with continuous shaking for 30 minutes at 37oC. At the end of the incubation period, the incubate is diluted with 5 ml of ice-cold Krebs-Hepes buffer and immediately vacuum filtered through Whatman GF/B filters, followed by two 5ml washes with ice-cold Krebes-Hepes buffer. The filters are dried and counted in 10 ml of liquid scintillation cocktail. Specific GR 65630 binding is defined as the difference between the total binding and that bound in the presence of 100uM GR38032F. IC values were derived from computer-derived log-probit analysis.

Various compounds of the invention were subjected to the above-described assay and the results the affinity for 5 HT 3 receptors are reported in Table I, below.

TABLE I Affinity for 5-HT 3 Receptor-Displacement of 3 H-GR 65630 Compound ICS,uM Ex. 3 0.868 Ex. 4 0.083 Ex. 5 0.056 WO 97/25317 PCT/US96/19569 Ondansetron 0.089 (standard) ICS 205 930 0.039 (standard) Measurement of 5 HT Antagonist Effects in the Bezold-Jarisch Assay This assay evaluates the effect of these compounds as antagonists. They were examined in this assay on the coronary chemoreflex (Bezold-Jarisch) initiated by 5-HT, in vivo and characterized by leading inhibition of sympathetic outflow and increased activity of the cardiac vagus, leading.to profound bradycardia and hypotension. The values obtained allow for continuous monitoring of arterial pressure and heart rate responses by these compounds over an extended period of time to determine their effecicy for 5 HT, antagonism.

The catheters were prepared from Tygon tubing (45cm length, 0.05mm, ID) bonded to Teflon tubing (0.38mm, ID). The mechanical bonding was achieved by insertion of the Teflon tubing (5mm) into the dilated (ethylene dichloride, 3-4 min.) tip of the Tygon tubing. The junction was then sealed with vinyl glue, the catheters were soaked in cold sterilization solution (Amerse instrument germicide) and flushed thoroughly WO 97/25317 PCT/US96/19569 with saline prior to implantation.

Long Evans rats were anesthetized with sodium pentobarbital ip). The catheters filled with hepranized saline (100 U/ml) were inserted in the left femoral artery and vein and passed into the abdominal aorta and inferior vena cava, respectively. The catheters were then sutured to the underlying muscle and the free ends were passed subcutaneously and exteriorized through an incision on the top of the skull. The catheters were then secured to the skin with sutures, nitrofurazone powder was dusted over the area of the incision and the incision was closed using 3-0 silk sutures. The catheters were flushed with saline and sealed with metal obturators. Patentcy of the two catheters was maintained by daily flushing with hepranized saline (0.2 ml of 100 U/ml). The rats were given 48 hours recovery prior to obtaining cardiovascular data.

In the anesthetized rat model the catheters were not exteriorized, data was collected acutely under the influence of general anesthesia.

The baseline data Arterial Blood Pressure(mm Hg, systolic/diastolic) and Heart Rate (beats/min) were recorded and the rats were injected with 5-HT (3-7.5ug/kg, iv). The WO 97/25317 PCT/US96/19569 individual response to the 5-HT intervention was determined and the compound was then administered singlely or in an ascending dose range. The rats were challenged with 5-HT again at intervals postdosing and the peak response was recorded.

Several compounds of the invention were tested according to the above-described assay and the results are reported in Table II, below.

WO 97/25317PC/S/196 PCTIUS96/19569 TAB3LE I I Inhibitory Potency of 5-HT 3 Antagonists on Reflex Bradycardia Induced by Intravenous 5-HT3 in the Anesthetized Long-Evans Rat Compound Dose, mg/kg, ip Inhibition of Bezold-Jarisch Reflex (Values are mean t SF24, 2-3 rats/dose) 57.3 t 9.7 94.6 t 2.7 58.6 t 16.4 9 Ondansetron 3.0 i

I

Ondansetron 10.0 i Ex. 4 0.03 6 6 Ex. 4 0.05 8 3 3 8 2 Ex. 4 0.10 93.0 Ex. 5 1.0 55.6 9.7 Ex. 5 13.0 89.3 2.9 In accordance with Table II, maximal reductions in heart rate induced by SHT, Bezold-Jarisch reflex) occurred 15 to minutes after administration.

Claims

4. 4 a a a a a. 4* a. a a a a a. a 0- CI_ a group of the formula a group of the formula N C \WINWOROV.JENNYM\SPECNKI\14 t26-97 DOC where R, is hydrogen, an alkyl group of 1 to 6 carbon atoms, optionally substituted with hydroxy, C1-C6 alkoxy, amino; aryl or heteroaryl, optionally substituted with halogen, hydroxy or C 1 -C 6 alkoxy; or benzyl optionally substituted with halogen, hydroxy or C,-C 6 alkoxy; n is an integer of 1 or 2; Z is N, CH or C(OH); m is an integer of 1 to 3; and X is hydrogen, hydroxy or C,-C6 alkoxy; the pharmaceutically acceptable salts thereof, the geometric or optional isomers thereof, or the racemic mixtures thereof, or hydrates thereof, where applicable. 2. A compound according to Claim 1, wherein A is a group of the formula N (CH 2 )m Ri wherein R, and m are as defined above. 3. A compound according to Claim 1, wherein A is a group of the formula 15 wherein R, is as defined above. 4. A compound according to Claim 1, wherein A is a group of the formula S: 015 wherein R, is as defined above. 4. A compound according to Claim 1, wherein A is a group of the formula a. wherein R 1 is as defined above. A compound according to Claim 1, wherein A is a group of the formula 7 C \WINWORDLJENNYM\SPECNKI\14126-97 DOC -46-
6. The compound according to Claim 1, which is a 3-chloro-4,5- dihydronaphth[1,2-c]isoxazole, or salts thereof.
7. The compound according to Claim 1, which is 3-hydroxy-8-methoxy-4,5- dihydronaphth[1,2-c]isoxazole, or salts thereof.
8. The compound according to Claim 1, which is 3-chloro-8-methoxy-4,5- dihydronaphth[1,2-c]isoxazole, or salts thereof.
9. The compound according to Claim 1, which is 5,6-dihydro-4H- benzo[6,7]cyclohept[1,2-c]isoxazol-3-ol, or salts thereof.
10. The compound according to Claim 2, which is 3-(4-methyl-1-piperazinyl)- 4,5-dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable salts thereof.
11. The compound according to Claim 2, which is 3-(4-(2-hydroxyethyl)-1- piperazinyl)-4,5-dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable salts thereof.
12. The compound according to Claim 2, which is 3-(1-homopiperazinyl)-4,5- dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable salts thereof.
13. The compound according to Claim 2, which is 3-(1-piperazinyl)-4,5- dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable salts thereof.
14. The compound according to Claim 2, which is 3-(1-piperazinyl)-8- S: .methoxy)-4,5-dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable salts thereof.
15. The compound according to Claim 2, which is 3-(1-homopiperazinyl)-8- methoxy)-4,5-dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable 25 salts thereof.
16. The compound according to Claim 2, which is 3-(1-(4-(p-chlorophenyl)-4- hydroxy-piperidinyl)-8-methoxy)-4,5-dihydronaphth[1,2-c]isozazole, or pharmaceutically acceptable salts thereof.
17. The compound according to Claim 2, which is fluorobenzisoxazol-3-yl)-piperidinyl)-8-methoxy)-4,5-dihydronaphth[1,2- c]isoxazole, or pharmaceutically acceptable salts thereof. C \WINWORDLJENNYM\SPECNKI\1412e97 DOC -47-
18. The compound according to Claim 2, which is 3-(1-(4-(2-oxo-1- benzimidazolynyl)piperidinyl)-8-methoxy)-4,5-dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable salts thereof.
19. The compound according to Claim 2, which is 3 benzimidazolinyl)piperidinyl))-4,5-dihydronaphth[1,2-c]isozazole, or pharmaceutically acceptable salts thereof. The compound according to Claim 3, which is 3[(1-methyl-4- piperidinyl)oxy]-4,5-dihydronaphth[1,2-c]isoxazole, or pharmaceutically acceptable salts thereof.
21. The compound according to Claim 4, which is 3-[(endo)-8-methyl-8- azabicyclo[3.2.1]oct-3-yl]-8-methoxy)-4,5-dihydronaphth[1,2-c]isoxazole, the pharmaceutically acceptable salts thereof, or geometric isomers thereof.
22. The compound according to Claim 4, which is 3-[(endo-8-methyl-8- azabicyclo[3.2.1 ]octo-3-yl)oxy]-4,5-dihydronaphth[1,2-c]isoxazole, the pharmaceutically acceptable salts thereof, or hydrates thereof.
23. The compound according to Claim 5, which is 3-[(quinuclidin-3-yl)oxy]-8- methoxy)-4,5-dihydronaphth[1,2-c]isoxazole, pharmaceutically acceptable salts thereof or optical isomers thereof, or racemic mixtures thereof.
24. A process for the preparation of a compound of the formula: -0 X (I) Where A is a group of the formula RI a group of the formula C \WINWORDWENNYM\SPECNKI414~26Y1 DOC -48- SORI a group of the formula a a a a. a a a a group of the formula N wherein R, is hydrogen, an alkyl group of 1 to 6 carbon atoms, optionally substituted with hydroxy, C 1 -C 6 alkoxy, amino; aryl or heteroaryl, optionally 10 substituted with halogen, hydroxy or C 1 -C 6 alkoxy; or benzyl optionally substituted with halogen, hydroxy or C,-C 6 alkoxy; n is an integer of 1 or 2; Z is N, CH or C(OH); m is an integer of 1 to 3; and X is hydrogen, hydroxy or C 1 -C 6 alkoxy; which comprises contacting a compound of the formula wherein X and n are as hereindefined with a compound of the formula HN (CI2)m D. C \WINWORDJENNYM\SPECNKI\I,25-9 DOC I -49- a compound of the formula HONI" N or "Ri a compound of the formula Ri I N or OH a compound of the formula 9 O-.HO 9o** 10 N wherein R, and m are as hereindefined. The process according to Claim 24, wherein the method is performed in the absence of a solvent.
26. The process according to Claim 24, wherein the method is performed in 15 the presence of a solvent.
27. The process according to Claim 26, wherein the solvent is N- methylpiperidine.
28. The process according to Claim 26, wherein the solvent is tetrahydrofuron.
29. The process according to Claim 26, wherein the solvent is hexanes. The process according to any one of claims 24 to 29, wherein a base is employed.
31. The process according to Claim 30, wherein the base is potassium Scarbonate. C \WINWORD\.JENNYM\SPECNKh\14126.97 DOC
32. The process according to Claim 30, wherein the base is n-butyllithium.
33. The process according to Claim 30, wherein the base is sodium hydride.
34. The process according to Claim 24, wherein the method is performed at a temperature from about 100°C to about 200 0 C.
35. A method of reducing nausea in a mammal in need of nausea reduction which comprises administering to such a mammal a nausea reducing effective amount of a compound of Claim 1.
36. A method of reducing vomiting in a mammal in need of vomiting reduction which comprises administering to such a mammal a vomiting reducing effective amount of a compound of Claim 1.
37. A method of treating anxiety in a mammal in need of anxiety treatment which comprises administering, to such a mammal an anxiety treating effective amount of a compound according to Claim 1.
38. A nausea reducing composition comprising an adjuvant and as the active ingredient, a nausea reducing effective amount of a compound according to Claim 1.
39. A vomiting reducing composition comprising an adjuvant and as the 4 active ingredient, a vomiting reducing effective amount of a compound according to Claim 1.
40. An anxiety treating composition comprising an adjuvant and as the active ingredient, an anxiety treating effective amount of a compound according to Claim 1. :41. A method of ameliorating anxiety, psychiatric disorders, schizophrenia, nausea, vomiting and drug dependency conditions in a mammal in need 4444 S 25 thereof, comprising administering a therapeutically effective amount of a serotonin antagonistic compound of claim 1.
42. Use of a compound according to Claim 1 for the preparation of a medicament for the treatment of nausea.
43. Use of a compound according to Claim 1 for the preparation of a medicament for the treatment of vomiting.
44. Use of a compound according to Claim 1 for the preparation of a medicament for the treatment of anxiety. C \WINWORD\JENNYM\SPECNKI\14126-97 DOC -51- A pharmaceutical composition comprising an effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier thereof.
46. A compounding according to any one of Claims 1 to 23 when produced by a method according to Claim 24.
47. A method according to Claim 24 substantially as hereinbefore described with reference to any of the examples. DATED 28 June, 1999 PHILLIPS ORMONDE FITZPATRICK Attorneys For: HOECHST MARION ROUSSEL, INC. to*V. o 0* S S C \WINWORDUENNYM\SPECNKI\14126-97 DOC